Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Canada
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2017
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms BIOFLOW-III
- Sponsors BIOTRONIK
- 29 Aug 2016 Status changed from active, no longer recruiting to completed.
- 08 Sep 2015 Planned End Date changed from 1 May 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 02 Feb 2015 Planned End Date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.